PURPOSE: Terminal oncology intensive care unit (ICU) hospitalizations are associated with high costs and inferior quality of care. This study identifies and characterizes potentially avoidable terminal admissions of oncology patients to ICUs. METHODS: This was a retrospective case series of patients cared for in an academic medical center's ambulatory oncology practice who died in an ICU during July 1, 2012 to June 30, 2013. An oncologist, intensivist, and hospitalist reviewed each patient's electronic health record from 3 months preceding terminal hospitalization until death. The primary outcome was the proportion of terminal ICU hospitalizations identified as potentially avoidable by two or more reviewers. Univariate and multivariate analysis were performed to identify characteristics associated with avoidable terminal ICU hospitalizations. RESULTS: Seventy-two patients met inclusion criteria. The majority had solid tumor malignancies (71%), poor performance status (51%), and multiple encounters with the health care system. Despite high-intensity health care utilization, only 25% had documented advance directives. During a 4-day median ICU length of stay, 81% were intubated and 39% had cardiopulmonary resuscitation. Forty-seven percent of these hospitalizations were identified as potentially avoidable. Avoidable hospitalizations were associated with factors including: worse performance status before admission (median 2 v 1; P = .01), worse Charlson comorbidity score (median 8.5 v 7.0, P = .04), reason for hospitalization (P = .006), and number of prior hospitalizations (median 2 v 1; P = .05). CONCLUSION: Given the high frequency of avoidable terminal ICU hospitalizations, health care leaders should develop strategies to prospectively identify patients at high risk and formulate interventions to improve end-of-life care.
PURPOSE: Terminal oncology intensive care unit (ICU) hospitalizations are associated with high costs and inferior quality of care. This study identifies and characterizes potentially avoidable terminal admissions of oncology patients to ICUs. METHODS: This was a retrospective case series of patients cared for in an academic medical center's ambulatory oncology practice who died in an ICU during July 1, 2012 to June 30, 2013. An oncologist, intensivist, and hospitalist reviewed each patient's electronic health record from 3 months preceding terminal hospitalization until death. The primary outcome was the proportion of terminal ICU hospitalizations identified as potentially avoidable by two or more reviewers. Univariate and multivariate analysis were performed to identify characteristics associated with avoidable terminal ICU hospitalizations. RESULTS: Seventy-two patients met inclusion criteria. The majority had solid tumor malignancies (71%), poor performance status (51%), and multiple encounters with the health care system. Despite high-intensity health care utilization, only 25% had documented advance directives. During a 4-day median ICU length of stay, 81% were intubated and 39% had cardiopulmonary resuscitation. Forty-seven percent of these hospitalizations were identified as potentially avoidable. Avoidable hospitalizations were associated with factors including: worse performance status before admission (median 2 v 1; P = .01), worse Charlson comorbidity score (median 8.5 v 7.0, P = .04), reason for hospitalization (P = .006), and number of prior hospitalizations (median 2 v 1; P = .05). CONCLUSION: Given the high frequency of avoidable terminal ICU hospitalizations, health care leaders should develop strategies to prospectively identify patients at high risk and formulate interventions to improve end-of-life care.
Authors: Alexi A Wright; Nancy L Keating; Tracy A Balboni; Ursula A Matulonis; Susan D Block; Holly G Prigerson Journal: J Clin Oncol Date: 2010-09-13 Impact factor: 44.544
Authors: Colleen C Apostol; Julie M Waldfogel; Elizabeth R Pfoh; Donald List; Lynn S Billing; Suzanne A Nesbit; Sydney Morss Dy Journal: Palliat Med Date: 2014-12-19 Impact factor: 4.762
Authors: Ronald M Kline; Carol Bazell; Erin Smith; Heidi Schumacher; Rahul Rajkumar; Patrick H Conway Journal: J Oncol Pract Date: 2015-02-17 Impact factor: 3.840
Authors: K Robin Yabroff; Elizabeth B Lamont; Angela Mariotto; Joan L Warren; Marie Topor; Angela Meekins; Martin L Brown Journal: J Natl Cancer Inst Date: 2008-04-29 Impact factor: 13.506
Authors: Daniel M Kobewka; Carl van Walraven; Jeffrey Turnbull; James Worthington; Lisa Calder; Alan Forster Journal: BMJ Qual Saf Date: 2016-02-08 Impact factor: 7.035
Authors: Corita R Grudzen; Lynne D Richardson; Pauline N Johnson; Ming Hu; Binhuan Wang; Joanna M Ortiz; Emmett A Kistler; Angela Chen; R Sean Morrison Journal: JAMA Oncol Date: 2016-05-01 Impact factor: 33.006
Authors: Paul R Duberstein; Richard L Kravitz; Joshua J Fenton; Guibo Xing; Daniel J Tancredi; Michael Hoerger; Supriya G Mohile; Sally A Norton; Holly G Prigerson; Ronald M Epstein Journal: J Pain Symptom Manage Date: 2019-04-18 Impact factor: 3.612
Authors: Gary E Weissman; Meeta Prasad Kerlin; Yihao Yuan; Rachel Kohn; George L Anesi; Peter W Groeneveld; Rachel M Werner; Scott D Halpern Journal: Ann Am Thorac Soc Date: 2020-01
Authors: Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton Journal: J Pain Symptom Manage Date: 2019-10-19 Impact factor: 3.612
Authors: Navpreet K Dhillon; Ara Ko; Eric J T Smith; Mayumi Kharabi; Joseph Castongia; Michael Nurok; Bruce L Gewertz; Eric J Ley Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: Andrew S Epstein; Andrew Yang; Lauren E Colbert; Louis P Voigt; Jason Meadows; Jessica I Goldberg; Leonard B Saltz Journal: J Intensive Care Med Date: 2017-12-20 Impact factor: 3.510